{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:15Z","timestamp":1791389295238,"version":"4.3.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,12]]},"DOI":"10.7759\/cureus.43360","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T10:51:49Z","timestamp":1691837509000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Dupilumab in Treating Atopic Dermatitis With Recurrent Eczema Herpeticum in a Patient With DOCK8-Deficiency Hyper-IgE Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Reshale A","family":"Johar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Hasanain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Khouqeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-018-0806-6","article-title":"Clinical manifestation of hyper ige syndrome including otitis media","volume":"18","author":"Wu J","year":"2018","unstructured":"Wu J, Hong L, Chen TX. Clinical manifestation of hyper ige syndrome including otitis media. Curr Allergy Asthma Rep. 2018, 18:51. 10.1007\/s11882-018-0806-6","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-2288","article-title":"DOCK8 mutation syndrome: a diagnostic challenge for dermatologists","volume":"96","author":"Moreau J","year":"2016","unstructured":"Moreau J, Beaussant-Cohen S, Aubin F, Rohrlich PS, Puzenat E. DOCK8 mutation syndrome: a diagnostic challenge for dermatologists. Acta Derm Venereol. 2016, 96:991-992.","journal-title":"Acta Derm Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02324-3","article-title":"Hyper-IgE Syndrome: recent progress in diagnosis and treatment","volume":"32","author":"Li Chunxiao Yu","year":"2014","unstructured":"Li Chunxiao Yu, Hong. Hyper-IgE Syndrome: recent progress in diagnosis and treatment. Clin Pediatr. 2014, 32:88-91. 10.1186\/s12883-021-02324-3","journal-title":"Clin Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.06.003","article-title":"DOCK8 deficiency: Insights into pathophysiology, clinical features and management","volume":"181","author":"Biggs CM","year":"2017","unstructured":"Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: Insights into pathophysiology, clinical features and management. Clin Immunol. 2017, 181:75-82. 10.1016\/j.clim.2017.06.003","journal-title":"Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-76","article-title":"The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency","volume":"6","author":"Szczawinska-Poplonyk A","year":"2011","unstructured":"Szczawinska-Poplonyk A, Kycler Z, Pietrucha B, Heropolitanska-Pliszka E, Breborowicz A, Gerreth K. The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis. 2011, 6:76. 10.1186\/1750-1172-6-76","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1945","article-title":"The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency","volume":"136","author":"Engelhardt KR","year":"2015","unstructured":"Engelhardt KR, Gertz ME, Keles S, et al.. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015, 136:402-12. 10.1016\/j.jaci.2014.12.1945","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.03.032","article-title":"Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-\u03b1 2b therapy","volume":"133","author":"Keles S","year":"2014","unstructured":"Keles S, Jabara HH, Reisli I, et al.. Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-\u03b1 2b therapy. J Allergy Clin Immunol. 2014, 133:1753-5.e3. 10.1016\/j.jaci.2014.03.032","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.262","article-title":"Cutaneous manifestations of DOCK8 deficiency syndrome","volume":"148","author":"Chu EY","year":"2012","unstructured":"Chu EY, Freeman AF, Jing H, et al.. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012, 148:79-84. 10.1001\/archdermatol.2011.262","journal-title":"Arch Dermatol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02324-3","article-title":"Autosomal recessive hyper-IgE syndrome caused by DOCK8 gene mutation with new clinical features: a case report","volume":"21","author":"Yang J","year":"2021","unstructured":"Yang J, Liu Y. Autosomal recessive hyper-IgE syndrome caused by DOCK8 gene mutation with new clinical features: a case report. BMC Neurol. 2021, 21:288.","journal-title":"BMC Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9664-5","article-title":"Additional diverse findings expand the clinical presentation of DOCK8 deficiency","volume":"32","author":"Sanal O","year":"2012","unstructured":"Sanal O, Jing H, Ozgur T, et al.. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol. 2012, 32:698-708. 10.1007\/s10875-012-9664-5","journal-title":"J Clin Immunol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1002\/cia2.12273","article-title":"Autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency: an adjunctive role for omalizumab","volume":"5","author":"Nguyen KH","year":"2022","unstructured":"Nguyen KH, Nguyen QA, Tran MH, et al.. Autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency: an adjunctive role for omalizumab. J Cutan Immunol Allergy. 2022, 5:222-226.","journal-title":"J Cutan Immunol Allergy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0126-0","article-title":"DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients","volume":"35","author":"Aydin SE","year":"2015","unstructured":"Aydin SE, Kilic SS, Aytekin C, et al.. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol. 2015, 35:189-98. 10.1007\/s10875-014-0126-0","journal-title":"J Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.038","article-title":"Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome","volume":"124","author":"Engelhardt KR","year":"2009","unstructured":"Engelhardt KR, McGhee S, Winkler S, et al.. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009, 124:1289-302.e4. 10.1016\/j.jaci.2009.10.038","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06295.x","article-title":"DOCK8 deficiency","volume":"1246","author":"Su HC","year":"2011","unstructured":"Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci. 2011, 1246:26-33. 10.1111\/j.1749-6632.2011.06295.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905506","article-title":"Combined immunodeficiency associated with DOCK8 mutations","volume":"361","author":"Zhang Q","year":"2009","unstructured":"Zhang Q, Davis JC, Lamborn IT, et al.. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009, 361:2046-55. 10.1056\/NEJMoa0905506","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201141759","article-title":"DOCK8 is essential for T-cell survival and the maintenance of CD8+ T-cell memory","volume":"41","author":"Lambe T","year":"2011","unstructured":"Lambe T, Crawford G. DOCK8 is essential for T-cell survival and the maintenance of CD8+ T-cell memory. Eur J Immunol. 2011, 41:3423-35.","journal-title":"Eur J Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.03.002","article-title":"Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait","volume":"143","author":"Al-Herz W","year":"2012","unstructured":"Al-Herz W, Ragupathy R, Massaad MJ, et al.. Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. Clin Immunol. 2012, 143:266-72. 10.1016\/j.clim.2012.03.002","journal-title":"Clin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.297","article-title":"Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches","volume":"15","author":"Constant SL","year":"1997","unstructured":"Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997, 15:297-322. 10.1146\/annurev.immunol.15.1.297","journal-title":"Annu Rev Immunol"},{"key":"ref19","article-title":"Dupilumab (Dupixent): an Interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D'Ippolito D","year":"2018","unstructured":"D'Ippolito D, Pisano M. Dupilumab (Dupixent): an Interleukin-4 receptor antagonist for atopic dermatitis. P T. 2018, 43:532-5.","journal-title":"P T"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4934.4934","article-title":"Hyper Immunoglobulin E Syndrome (HIES): report of a new case treated with omalizumab and dexametasone","volume":"118","author":"Cort\u00e1zar-Ben\u00edtez LF","year":"2011","unstructured":"Cort\u00e1zar-Ben\u00edtez LF, Rojas Sotelo RM. Hyper Immunoglobulin E Syndrome (HIES): report of a new case treated with omalizumab and dexametasone. Blood. 2011, 118:4934-4.","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/154909-efficacy-of-dupilumab-in-treating-atopic-dermatitis-with-recurrent-eczema-herpeticum-in-a-patient-with-dock8-deficiency-hyper-ige-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:40Z","timestamp":1707508900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/154909-efficacy-of-dupilumab-in-treating-atopic-dermatitis-with-recurrent-eczema-herpeticum-in-a-patient-with-dock8-deficiency-hyper-ige-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.43360","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,12]]}}}